These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33153828)

  • 1. Quetiapine treatment for cannabis use disorder.
    Mariani JJ; Pavlicova M; Jean Choi C; Basaraba C; Carpenter KM; Mahony AL; Brooks DJ; Bisaga A; Naqvi N; Nunes EV; Levin FR
    Drug Alcohol Depend; 2021 Jan; 218():108366. PubMed ID: 33153828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
    Gao K; Ganocy SJ; Conroy C; Brownrigg B; Serrano MB; Calabrese JR
    Psychopharmacology (Berl); 2017 Aug; 234(15):2233-2244. PubMed ID: 28536866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label pilot study of quetiapine treatment for cannabis dependence.
    Mariani JJ; Pavlicova M; Mamczur AK; Bisaga A; Nunes EV; Levin FR
    Am J Drug Alcohol Abuse; 2014 Jul; 40(4):280-4. PubMed ID: 24963729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
    D'Souza DC; Cortes-Briones J; Creatura G; Bluez G; Thurnauer H; Deaso E; Bielen K; Surti T; Radhakrishnan R; Gupta A; Gupta S; Cahill J; Sherif MA; Makriyannis A; Morgan PT; Ranganathan M; Skosnik PD
    Lancet Psychiatry; 2019 Jan; 6(1):35-45. PubMed ID: 30528676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
    Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
    Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
    Freeman TP; Hindocha C; Baio G; Shaban NDC; Thomas EM; Astbury D; Freeman AM; Lees R; Craft S; Morrison PD; Bloomfield MAP; O'Ryan D; Kinghorn J; Morgan CJA; Mofeez A; Curran HV
    Lancet Psychiatry; 2020 Oct; 7(10):865-874. PubMed ID: 32735782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
    Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
    Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial.
    Gilbert DG; Rabinovich NE; McDaniel JT
    Psychopharmacology (Berl); 2020 May; 237(5):1507-1519. PubMed ID: 32034447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-abstinent treatment outcomes for cannabis use disorder.
    Levin FR; Mariani JJ; Choi CJ; Basaraba C; Brooks DJ; Brezing CA; Pavlicova M
    Drug Alcohol Depend; 2021 Aug; 225():108765. PubMed ID: 34087745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
    Cooper ZD; Foltin RW; Hart CL; Vosburg SK; Comer SD; Haney M
    Addict Biol; 2013 Nov; 18(6):993-1002. PubMed ID: 22741619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.
    Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR
    Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial.
    McRae-Clark AL; Gray KM; Baker NL; Sherman BJ; Squeglia L; Sahlem GL; Wagner A; Tomko R
    Drug Alcohol Depend; 2021 Dec; 229(Pt B):109111. PubMed ID: 34655945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
    Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
    Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.
    Findling RL; Pathak S; Earley WR; Liu S; DelBello MP
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):325-35. PubMed ID: 24956042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
    Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
    Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.
    Sugarman DE; De Aquino JP; Poling J; Sofuoglu M
    Pharmacol Biochem Behav; 2019 Jun; 181():86-92. PubMed ID: 31082417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.
    Squeglia LM; Tomko RL; Baker NL; McClure EA; Book GA; Gray KM
    Drug Alcohol Depend; 2018 Apr; 185():17-22. PubMed ID: 29413434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.